Cover Image

Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?

Saved in:

Bibliographic Details
Main Authors:	Eunjin Hong (Author), Paul M. Beringer (Author)
Format:	Book
Published:	Wiley, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Response to "Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?"
by: Magali Amiel
Published: (2024)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients
by: Eunjin Hong, et al.
Published: (2023)

Physiologically‐based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients
by: Magali Amiel, et al.
Published: (2024)

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
by: M Tod, et al.
Published: (2017)

Response to "Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?"
by: IE Templeton, et al.
Published: (2017)

A guide to developing population files for physiologically‐based pharmacokinetic modeling in the Simcyp Simulator
by: Liam Curry, et al.
Published: (2024)

Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations
by: Hafsa Hafsa, et al.
Published: (2022)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
by: A R Maharaj, et al.
Published: (2014)

Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs
by: Sara Bettonte, et al.
Published: (2024)

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations
by: Mohammed S. Alasmari, et al.
Published: (2022)

A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations
by: Muhammad Talha Zahid, et al.
Published: (2023)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
by: Stefan Willmann, et al.
Published: (2019)

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities
by: Jean Dinh, et al.
Published: (2023)

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug
by: Farzaneh Salem, et al.
Published: (2023)

Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
by: Abdul Naveed Shaik, et al.
Published: (2019)

The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development
by: Cvijić Sandra, et al.
Published: (2021)

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans
by: Yoo-Seong Jeong, et al.
Published: (2021)

Animal Models in the Pathophysiology of Cystic Fibrosis
by: Anna Semaniakou, et al.
Published: (2019)

Unravelling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
by: Xiaoxia eYang, et al.
Published: (2015)

Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations
by: Muhammad F. Rasool, et al.
Published: (2019)

Development of a Physiologically-Based Pharmacokinetic Model of the Rat Central Nervous System
by: Raj K. Singh Badhan, et al.
Published: (2014)

Development of a Physiologically Based Pharmacokinetic Model for Nitrofurantoin in Rabbits, Rats, and Humans
by: Raju Prasad Sharma, et al.
Published: (2023)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
by: Yoo-Kyung Song, et al.
Published: (2021)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
by: Sumit Basu, et al.
Published: (2020)

Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs
by: Bin Yang, et al.
Published: (2017)

MEGen: A Physiologically Based Pharmacokinetic Model Generator
by: George D Loizou, et al.
Published: (2011)

Physiologically‐Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
by: Paul R. V. Malik, et al.
Published: (2019)

Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling
by: Venkata K. Yellepeddi, et al.
Published: (2021)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
by: Helen Humphries, et al.
Published: (2021)

A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
by: Hannah M. Jones, et al.
Published: (2019)

Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
by: J. R. Bosley, et al.
Published: (2021)

The burden of cystic fibrosis in the Medicaid population
by: Hassan M, et al.
Published: (2018)

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling
by: Karsten Menzel, et al.
Published: (2023)

Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics
by: Zaril Zakaria, et al.
Published: (2018)

Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations
by: Lingfeng Guo, et al.
Published: (2023)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
by: Chaozhuang Shen, et al.
Published: (2023)

Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
by: Xinxin Yang, et al.
Published: (2023)

Physiologically Based Pharmacokinetics Model in Pregnancy: A Regulatory Perspective on Model Evaluation
by: Paola Coppola, et al.
Published: (2021)

A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
by: Felix Stader, et al.
Published: (2019)

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
by: Estelle Yau, et al.
Published: (2023)